- Kohl's (KSS) up 6% after disclosing that its CEO Thomas Kingsbury bought 92.5K shares of common stock on March 29th in a total transaction size of $2.02M
Cazoo jumps 19% to $2.85 per share after FY22 results and guidance 09:01 CZOO
I know you know the whole SQ story. There was a Hindenberg report Short report.
HF got in beginning of week when it sold off. It's a good name. (I think)
It fell from $74 area. It was almost $78 prior. Dropped to 58 -- just back of envelope that's $20/divide by 2 = $10 // $10 up from $58 is $68 <-- That's fair value.
Gummy Daytrade:
Short Disney at $98.65
Stop at $99.10
![]()
![]()
![]()
![]()

The readers got stopped out at $1.50 I heard.HEY GUYS QUICK UPDATE-- I'M TRANSITIONING AGAIN TODAY-- BACK TO NYC MAN!
I HAVE A NEW CAR BATTERY!!!!
OK THIS IS WHY I GET PAID THE BIG BUCKS... I THINK YOU GUYS HOLD HERE
$2.47 <---- IS MY ST TARGET
SCYX SCYNEXIS, Inc.-- stay strong this will fly today!
$2.000.44 (+28.21%)4:00 PM 03/22/23
NASDAQ | $USD | Pre-Market: $2.11 +0.11 (+5.50%) 8:02 AM<------------![]()
$20.50 last trade.
Take the 33% win before they release #'s.
Or take most off.

BLUE got halted yesterday btw.1 NEW Buy today folks from the hottest stock picker this side of the Pacific /////
bluebird bio, Inc.
$4.17-0.79 (-15.93%)4:00 PM 03/10/23
NASDAQ | $USD | Pre-Market: $4.37 +0.20 (+4.80%) --> It's Just To Cheap
Up 20%Back in Dec-
Pyxis Oncology announces FDA clearance of two IND applications 12/01/22 PYXS Pyxis Oncology announced that it has received clearance for its two Investigational New Drug applications from the U.S. FDA to initiate Phase 1 clinical trials. PYX-201, a novel antibody-drug conjugate product candidate, will be investigated for the potential treatment of several solid tumors, including breast, head and neck, lung, and thyroid cancer. PYX-106, an immunotherapy product candidate, will be investigated for the potential treatment of solid tumors, including bladder, cholangio-carcinoma, colorectal, and kidney cancer. Trials are expected to begin in early 2023.
Then March 21_>Pyxis Oncology discloses $5M purchase of common stock by Pfizer 03/21 PYXS, PFE In a regulatory filing, Pyxis Oncology (PYXS) disclosed that Pfizer (PFE) bought 1.8M shares of common stock on March 17th in a total transaction size of $5.0M. Shares of Pyxis Oncology are up 26% afterhours at $2.78.<---
That's what set it off. Pfizer makes a lot of small investments I think you can move on.
Up 40%!Up 20%